- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06321458
Intensive Weight Loss Intervention Versus Usual Care for Adults With Severe and Complex Obesity (LightWAY)
Intensive Weight Loss Intervention Versus Usual Care for Adults With Severe and Complex Obesity: the LightWAY Randomised Trial: Lighthouse Consortium on Obesity Management (LightCOM) Trial no 3
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the LightWAY trial, an intensive weight loss (IWL) intervention will be compared with with usual care. The IWL lasts two years, and includes total dietary replacements, behavioural support, and weight loss medication in three phases:
- Induction' phase (week 0-12 after randomisation): total dietary replacement (TDR) programme and behavioural support with weight loss medication (WLM) if rate of weight loss is insufficient.
- Weight loss continuation' phase (week 13-32 after randomisation): progression of dietary programme including reduction in use of TDR products, reintroduction of healthy foods, with behavioural support, introduction of physical activity, WLM (as required).
- Maintenance' phase (week 33-104 after randomisation): Continued healthy diet and physical activity with WLM (if required), with return to induction phase if weight regain occurs induction, weight loss continuation, maintenance.
Usual care will differ between the two countries (Denmark and the United Kingdom).
In Denmark, participants will receive a pamphlet on current obesity management guidelines from the Danish National Board of Health, and will be advised to contact their GP for potential referral to local municipality-based obesity management programmes. Furthermore, a notification will be sent to the participant's GP, informing that the participant has been enrolled in the trial and is randomised to usual care. The availability and structure of current obesity programmes varies between municipalities.
In the United Kingdom, participants are eligible for referral into an NHS Tier 3 weight management service. These services are commissioned by integrated care boards, and can therefore differ slightly across the 42 regions within the UK. These are specialist weight management clinics that provide non-surgical, intensive medical management with a multidisciplinary approach to care. These clinics often consist of specialist doctors, nurses, dieticians and physiotherapists/exercise therapists, and include psychological support.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carsten Dirksen, Ass. Prof.
- Phone Number: +45 29425320
- Email: carsten.dirksen@regionh.dk
Study Contact Backup
- Name: Susan Jebb, Professor
- Phone Number: +44 (0) 1865 617 831
- Email: lightcom@phc.ox.ac.uk
Study Locations
-
-
-
Frederiksberg, Denmark, 2000
- Not yet recruiting
- Frederiksberg kommune: Social-, Sundheds- og Arbejdsmarkedsområdet
-
Contact:
- Addie J Frederiksen
-
Frederiksberg, Denmark, 2000
- Not yet recruiting
- The Parker Institute, Copenhagen University Hospital - Bispebjerg and Frederiksberg
-
Contact:
- Sofus C Larsen
-
Hvidovre, Denmark, 2650
- Recruiting
- The Department of Medicine and the Gastro Unit, Copenhagen University Hospital - Amager and Hvidovre
-
Contact:
- Carsten Dirksen
-
Hvidovre, Denmark, 2650
- Not yet recruiting
- Hvidovre kommune: Center for Sundhed og Ældre, Hvidovre Sundhedscenter, Sundhed og Forebyggelse
-
Contact:
- Maria Bleiback Clausen
-
Søborg, Denmark, 2860
- Not yet recruiting
- Gladsaxe kommune: Social- og Sundhedsforvaltningen, Sundhed og Rehabilitering
-
Contact:
- Julie Borgen Braget
-
-
-
-
-
Oxford, United Kingdom
- Not yet recruiting
- IHR CRN: Thames Valley and South Midlands
-
Contact:
- Susan Jebb
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Please note that participants need to be invited in order to take part in the trial
Inclusion Criteria:
- Age ≥18 years and ≤60 years old at screening.
- Has severe and complex obesity i.e. BMI>35 or >32.5 in people with South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds and with one or more of these specific adiposity-related chronic diseases of cardiovascular disease, type 2 diabetes, hypertension, non-alcoholic steatosis, or sleep apnoea.
- Provides informed consent.
Exclusion Criteria:
- Intending to become pregnant in the next two years or pregnant or breastfeeding.
- Use of WLM or GLP-1 agonist treatment within the last three months.
- Currently being treated for cancer other than oestrogen antagonist therapy or non-melanoma skin cancer.
- Prior bariatric surgery, not including laparoscopic gastric banding, intragastric balloons or duodenal-jejunal bypass sleeve (Endobarrier™ or similar) if the device has been removed >1 year before screening.
- Diagnosis of or treatment for severe eating disorder within the last 6 months.
- Any other disease that markedly compromises the participant's ability to adhere to the treatment programme or follow-up or is likely to mean that weight loss will not improve the person's length or quality of life, such as conditions limiting life expectancy.
- Conditions that contraindicate or complicate TDR (including type 1 diabetes or other diabetes requiring insulin therapy, phenylketonuria, coeliac disease, or other conditions requiring special diets).
- Conditions that contraindicate or complicate GLP-1 treatment (including history of pancreatitis)
- Taking part in other research involving multidisciplinary obesity treatment would compromise participation in this trial.
- Another member of the household enrolled in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive weight loss intervention
The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication.
The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
|
Intensive weight loss intervention, incl.
total meal replacements, behavioural support, and weight loss medication.
|
Active Comparator: Usual care
Denmark: usual care offered by the GP or local municipality.
The UK: tier 3 weight management services.
|
Usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: 104 weeks after randomisation
|
Weight (kg)
|
104 weeks after randomisation
|
MetS-Z
Time Frame: 104 weeks after randomisation
|
Metabolic syndrome severity Z-score (scale from -4 to 4, mean is 0, higher scores indicate a worse outcome)
|
104 weeks after randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait speed
Time Frame: 104 weeks after randomisation
|
4-metre gait speed (m/s)
|
104 weeks after randomisation
|
Short-Form-36, mental component score
Time Frame: 104 weeks after randomisation
|
Quality of life, SF36-mental component score (scale from 0-100, higher scores indicate better mental health)
|
104 weeks after randomisation
|
Weight loss (20%)
Time Frame: 104 weeks after randomisation
|
Proportion of participants with weight loss ≥20%
|
104 weeks after randomisation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Labour market attachment - WPAI
Time Frame: 104 weeks after randomisation
|
Work productivity and impairment (WPAI) score points (scale from 0-100, higher scores indicate more limitations in ability to work and lower productivity)
|
104 weeks after randomisation
|
Labour market attachment - days of sick leave
Time Frame: 104 weeks after randomisation
|
Self-reported number of days sick leave during follow-up
|
104 weeks after randomisation
|
Health economy: Within-trial cost-effectiveness analysis - costs
Time Frame: 104 weeks after randomisation
|
24-month costs, DKK
|
104 weeks after randomisation
|
Health economy: Within-trial cost-effectiveness analysis - QALY
Time Frame: 104 weeks after randomisation
|
Incremental cost per quality-adjusted-life-year (QALY) gained, DKK
|
104 weeks after randomisation
|
Health economy: Model-based cost-effectiveness analysis - QALY
Time Frame: 104 weeks after randomisation
|
Predicted lifetime QALYs gained
|
104 weeks after randomisation
|
Health economy: Model-based cost-effectiveness analysis - healthcare costs
Time Frame: 104 weeks after randomisation
|
Predicted lifetime healthcare costs, DKK
|
104 weeks after randomisation
|
Health economy: Model-based cost-effectiveness analysis - cost effectiveness ratios
Time Frame: 104 weeks after randomisation
|
Long-term incremental cost effectiveness ratios
|
104 weeks after randomisation
|
Long-term effects - prescription patterns
Time Frame: 5, 10 and 20 years after randomisation
|
|
5, 10 and 20 years after randomisation
|
SAE
Time Frame: 104 weeks after randomisation
|
Proportion of participants with at least one serious adverse event during the intervention period (according to ICH-GCP guidelines)
|
104 weeks after randomisation
|
Incident eating disorders
Time Frame: 104 weeks after randomisation
|
Proportion of participants with incident eating disorders during the intervention period
|
104 weeks after randomisation
|
Body composition - waist circumference
Time Frame: 104 weeks after randomisation
|
Waist circumference (cm)
|
104 weeks after randomisation
|
Body composition - fat percentage
Time Frame: 104 weeks after randomisation
|
|
104 weeks after randomisation
|
Body composition - weight loss (10%)
Time Frame: 104 weeks after randomisation
|
Proportion of participants with weight loss ≥10%
|
104 weeks after randomisation
|
Physical functioning - SENS
Time Frame: 104 weeks after randomisation
|
Objectively measured moderate to vigorous physical activity (MVPA) using SENS Motion accelerometers (hours/day)
|
104 weeks after randomisation
|
Physical functioning - SF-36
Time Frame: 104 weeks after randomisation
|
Short Form 36 (SF-36) physical component score (scale from 0-100, higher scores indicate better physical health)
|
104 weeks after randomisation
|
Physical functioning - sit to stand test
Time Frame: 104 weeks after randomisation
|
Number of sit to stands completed in the 30 Second Sit to Stand test
|
104 weeks after randomisation
|
Sleep
Time Frame: 104 weeks after randomisation
|
Sleep duration using SENS Motion accelerometers (hours/day)
|
104 weeks after randomisation
|
Medications during the intervention period
Time Frame: 104 weeks after randomisation
|
|
104 weeks after randomisation
|
Metabolic health - blood pressure
Time Frame: 104 weeks after randomisation
|
Systolic and diastolic blood pressure (mmHg)
|
104 weeks after randomisation
|
Metabolic health - pulse
Time Frame: 104 weeks after randomisation
|
Pulse rate (beats per minute)
|
104 weeks after randomisation
|
Metabolic health - Hb1Ac
Time Frame: 104 weeks after randomisation
|
Haemoglobin A1c (mmol/mol)
|
104 weeks after randomisation
|
Metabolic health - insulin
Time Frame: 104 weeks after randomisation
|
Fasting insulin concentration (pmol/L)
|
104 weeks after randomisation
|
Metabolic health - HOMA2-IR
Time Frame: 104 weeks after randomisation
|
HOMA2-IR (calculated from glucose and C-peptide concentration) (ratio)
|
104 weeks after randomisation
|
Metabolic health - lipids
Time Frame: 104 weeks after randomisation
|
Fasting lipid profile (HDL, LDL and triglycerides) (mmol/L)
|
104 weeks after randomisation
|
Metabolic health - eGFR
Time Frame: 104 weeks after randomisation
|
Estimated Glomerular Filtration Rate (eGFR), creatinine (µmol/L), calculated from creatinine, sex and years
|
104 weeks after randomisation
|
Metabolic health - hsCRP
Time Frame: 104 weeks after randomisation
|
High-sensitivity C-reactive protein (hsCRP), mg/L
|
104 weeks after randomisation
|
Metabolic health - Fib4
Time Frame: 104 weeks after randomisation
|
Fib-4 (ALT/AST/platelets) (ratio)
|
104 weeks after randomisation
|
Metabolic health - proteinuria
Time Frame: 104 weeks after randomisation
|
Proteinuria, measured as urine albumin/creatinine (ratio)
|
104 weeks after randomisation
|
Metabolic health - TSH
Time Frame: 104 weeks after randomisation
|
Thyroid-stimulating hormone (IU/L)
|
104 weeks after randomisation
|
Mental health - MDI
Time Frame: 104 weeks after randomisation
|
Major Depression Inventory (MDI) (scale from 0-50, higher scores indicate more symptoms of depression)
|
104 weeks after randomisation
|
Mental health - WBIS-M
Time Frame: 104 weeks after randomisation
|
Weight Bias Internalization Scale (WBIS-M) score (scale from 1-7, higher scores indicate higher degree of internalised weight bias)
|
104 weeks after randomisation
|
Mental health - EDE-Q
Time Frame: 104 weeks after randomisation
|
Eating Disorder Examination Questionnaire (EDE-Q) score (scale from 0 to 6, higher scores indicate higher degree of eating disorder)
|
104 weeks after randomisation
|
Genetic profiles' (using comprehensive genetic mapping) association with the metabolic and/or weight loss response to IWL vs usual care
Time Frame: 104 weeks after randomisation
|
|
104 weeks after randomisation
|
Long-term effects - mortality and major cardiovascular disease (CVD)
Time Frame: 5, 10 and 20 years after randomisation
|
|
5, 10 and 20 years after randomisation
|
Long-term effects - incident cancer
Time Frame: 5, 10 and 20 years after randomisation
|
|
5, 10 and 20 years after randomisation
|
Long-term effects - fracture risk
Time Frame: 5, 10 and 20 years after randomisation
|
|
5, 10 and 20 years after randomisation
|
Long-term effects - health economic and labour market attachment, employment status
Time Frame: 5, 10 and 20 years after randomisation
|
Employment status for each participant
|
5, 10 and 20 years after randomisation
|
Long-term effects - health economic and labour market attachment, salary
Time Frame: 5, 10 and 20 years after randomisation
|
Salary for each participant
|
5, 10 and 20 years after randomisation
|
Long-term effects - health economic and labour market attachment, absence
Time Frame: 5, 10 and 20 years after randomisation
|
Number of absence days
|
5, 10 and 20 years after randomisation
|
Long-term effects - health economic and labour market attachment, sick leave
Time Frame: 5, 10 and 20 years after randomisation
|
Proportion of participants with any sick leave
|
5, 10 and 20 years after randomisation
|
Long-term effects - health economic and labour market attachment, long-term sick leave
Time Frame: 5, 10 and 20 years after randomisation
|
Proportion of participants with long-term sick leave (more than 4 weeks continuous sickness absence)
|
5, 10 and 20 years after randomisation
|
Bone mineral density (BMD) assessed by DXA
Time Frame: 104 weeks after randomisation
|
|
104 weeks after randomisation
|
Health economy: Within-trial cost-effectiveness analysis - quality of life, index score
Time Frame: 104 weeks after randomisation
|
Quality of life (measured using the 5-level EQ-5D version, EQ-5D-5L index score (score between -1 and 1, higher scores indicate better health)
|
104 weeks after randomisation
|
Health economy: Within-trial cost-effectiveness analysis - quality of life, VAS
Time Frame: 104 weeks after randomisation
|
Quality of life (measured using the 5-level EQ-5D version, EQ-5D-5L VAS score (scale from 0-100, higher scores indicate better health)
|
104 weeks after randomisation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Carsten Dirksen, Department of Medicine, Copenhagen University Hospital - Amager and Hvidovre
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LightWAY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Usual care
-
Charite University, Berlin, GermanyCompletedMultiple Sclerosis | FatigueGermany
-
Centers for Disease Control and PreventionCompleted
-
Charite University, Berlin, GermanyMammazentrum Hamburg am Krankenhaus Jerusalem, Germany; Dorit und Alexander...Completed
-
European Institute for Evidence Based Osteopathic...Unknown
-
Suzanna ZickUniversity of MichiganTerminatedQuality of Life | Fatigue | Lupus Erythematosus, Systemic | Sleep | Pain, ChronicUnited States
-
The Miriam HospitalNational Institute on Aging (NIA)RecruitingHeart FailureUnited States
-
Lawson Health Research InstituteUnknownDepression | Quality of Life | Sleep | Anxiety | Dry EyeCanada
-
U.S. Wound RegistryRecruitingWounds and Injuries | Diabetic Foot | Leg Ulcer | Skin Ulcer | Diabetes Complications | Diabetic Neuropathies | Lymphedema | Peripheral Arterial Disease | Vasculitis | Venous Insufficiency | Varicose Ulcer | Pressure Ulcer | Pyoderma | Surgical Wound Dehiscence | Amputation StumpUnited States
-
University Hospital, MontpellierCompletedOsteoarthritis | Mindfulness | MBSRFrance
-
Gachon University Gil Oriental Medical HospitalKorea Health Industry Development InstituteCompletedKnee Replacement | AcupunctureKorea, Republic of